Literature DB >> 17045339

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

Bernard J Scallon1, Susan H Tam, Stephen G McCarthy, Ann N Cai, T Shantha Raju.   

Abstract

Although it is now clear that certain Fc glycan structures on immunoglobulin G (IgG) antibodies (Abs) can have a dramatic influence on binding to selected Fcgamma receptors (FcgammaR) and on Fc-mediated immune functions, the effects of all known Fc glycan structures still have not been exhaustively studied. We report that in vitro analyses of pairs of monoclonal human IgG Abs that differ in the amount of sialic acid in their Fc glycans revealed that, for each of the three Ab pairs we examined, higher levels of sialylation were associated with reduced activity in Ab-dependent cellular cytotoxicity (ADCC) assays. This relationship between sialylation and ADCC activity was observed regardless of whether the differences in the extent of sialylation were derived by different Ab production processes, use of a lectin column to separate monoclonal Ab preparations into differentially sialylated fractions, or use of direct in vitro glycoengineering methods to convert a lesser sialylated Ab into a highly sialylated Ab. Subsequent investigations revealed that, depending on the individual Ab and how the differences in sialylation were derived, the lower ADCC potency of the more sialylated variants was apparently due to lower-affinity binding to FcgammaRIIIa on natural killer (NK) cells and/or, more interestingly, lower-affinity binding to cell-surface antigen. Our data provide the first example of an Fc glycan structure impacting antigen binding and suggest that avoiding Fc glycan sialylation can offer another means of optimizing ADCC activity of Abs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045339     DOI: 10.1016/j.molimm.2006.09.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  106 in total

1.  An innovative approach for the characterization of the isoforms of a monoclonal antibody product.

Authors:  Shanmuuga Sundaram; Alice Matathia; Jun Qian; Jingming Zhang; Ming-Ching Hsieh; Tun Liu; Richard Crowley; Babita Parekh; Qinwei Zhou
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 2.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

3.  Analysis of site-specific N-glycan remodeling in the endoplasmic reticulum and the Golgi.

Authors:  Ivan Hang; Chia-wei Lin; Oliver C Grant; Susanna Fleurkens; Thomas K Villiger; Miroslav Soos; Massimo Morbidelli; Robert J Woods; Robert Gauss; Markus Aebi
Journal:  Glycobiology       Date:  2015-08-03       Impact factor: 4.313

Review 4.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

5.  Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.

Authors:  Benjamin M Fiebiger; Jad Maamary; Andrew Pincetic; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

6.  Galactosylation variations in marketed therapeutic antibodies.

Authors:  T Shantha Raju; Robert E Jordan
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

7.  Using cell engineering and omic tools for the improvement of cell culture processes.

Authors:  Darrin Kuystermans; Britta Krampe; Halina Swiderek; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2007-02-24       Impact factor: 2.058

Review 8.  IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease.

Authors:  Jing Xue; Li-Ping Zhu; Qiang Wei
Journal:  Glycoconj J       Date:  2013-06-20       Impact factor: 2.916

Review 9.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

Review 10.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.